Literature DB >> 750109

Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.

F D Juma, H J Rogers, J R Trounce, I D Bradbrook.   

Abstract

A simple gas chromatographic assay utilising alkali flame ionisation detection is described for the estimation of cyclophosphamide as its trifluoroacetate derivative from plasma. Examination of five patients following intravenous cyclophosphamide gave values of 8.9 h (SD 2.7) for the half-life and 0.061 liters/h/kg (SD 0.011) for whole-body clearance of the drug.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 750109     DOI： 10.1007/bf00257155

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Studies on the disposition of cyclophosphamide (NSC-26271) in tumor-bearing mice by means of gas chromatography-chemical ionization-mass fragmentography.

Authors:  C Pantarotto; A Martini; G Belvedere; M G Donelli; A Frigerio
Journal:  Cancer Treat Rep       Date:  1976-04

2.  Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

Authors:  C Fenselau; M N Kan; S S Rao; A Myles; O M Friedman; M Colvin
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

3.  Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.

Authors:  C Pantarotto; A Bossi; G Belvedere; A Martini; M G Donelli; A Frigerio
Journal:  J Pharm Sci       Date:  1974-10       Impact factor: 3.534

4.  [Quantitative determination of alkylating cytostatics on TLC plate with 4-pyridinecarboxaldehyde-2-benzothiazolylhydrazone].

Authors:  K Norpoth; H W Addicks; U Witting
Journal:  Arzneimittelforschung       Date:  1973-11

5.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

6.  Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.

Authors:  I Jardine; R Brundrett; M Colvin; C Fenselau
Journal:  Cancer Treat Rep       Date:  1976-04

7.  Pharmacokinetics of cyclophosphamide in man.

Authors:  J L Cohen; J Y Jao; W J Jusko
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739
  7 in total
  23 in total

1.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 3.  The risks of handling cytotoxic drugs. I. Methods of testing exposure.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

4.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 5.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.

Authors:  R Pearcey; R Calvert; A Mehta
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Effect of liver failure on the pharmacokinetics of cyclophosphamide.

Authors:  F D Juma
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma.

Authors:  F D Juma; D K Koech; E G Kasili; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

9.  Pharmacokinetics of cyclophosphamide in Kenyan Africans.

Authors:  F Juma; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

10.  Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.